Replies to post #141747 on Biotech Values

[gfp927z]

Mcbio, >> PYMX <<

The anticoagulant reversal program was never the main reason to own Polymedix, but hopefully it may have some salvage value to a large pharma with the resources to test it using longer infusion times.

The antibiotic program (defensin mimetics) is the main reason to be interested in PYMX, and those programs are solid. Today could be a good buying opportunity for believers in this technology. Bacterial resistance is unable to develop to PYMX's defensin mimetic antibiotics, so it's a huge breakthrough.

[DewDiligence]

PYMX—As you may recall, I never thought much of this heparin-reversal program and stated on several occasions that the idea had little commercial potential.